Abstract. The effect of a schedule of three daily injections of 100 \g=m\g octreotide (pen treatment) compared with that of a continuous sc infusion of 300 \g=m\g/24 h on GH and IGF-I suppression, and other GH-dependent parameters was studied in 10 acromegalic patients in a cross-over study. (4, 5) . However, the required daily dose can vary considerably between patients, and doses of up to 1500 ng/day may be necessary (6,7). Since octreotide has a plasma half-time of 113 min after sc injection, GH levels tend to rise after 6-8 hours (8). Therefore, several groups of inves¬ tigators administered octreotide by continuous sc infusion, and compared its effect with intermittent injections. In these short-term studies sc infusion of octreotide for 2-3 days was more effective in sup¬ pressing GH levels than intermittent injections (9,10).
Abstract. The effect of a schedule of three daily injections of 100 \g=m\g octreotide (pen treatment) compared with that of a continuous sc infusion of 300 \g=m\g/24 h on GH and IGF-I suppression, and other GH-dependent parameters was studied in 10 acromegalic patients in a cross-over study. Treatment was administered via a specially designed pen or a pump for 4 weeks. Following a washout period of a further 4 weeks, patients were switched to the other mode of delivery. Mean GH levels decreased from 26.2\m=+-\4.7 to 9.9\m=+-\3.1 mU/l (p=0.007) during pen therapy and to 7.7\m=+-\2.4mU/l (p=0.003) during pump treatment.
IGF-I levels decreased from 75.6\m=+-\9.5to 42.0\m=+-\9.3nmol/l (p=0.003) during pen treatment and to 32.5\m=+-\2.5nmol/l (p=0.001) during pump treatment. There was a significant difference in IGF-I levels between pen and pump treatments (p=0.03). In 7 patients the IGF-I levels normalized during pump treatment compared with 3 patients in the pen treatment group. There was no change in the free T4 index levels, but the free T3 index significantly decreased during therapy, without changes in plasma TSH. This study demonstrates that continuous infusion with octreotide results in a better control of GH oversecretion than the intermittent mode of delivery.
Although the GH-lowering effect of somatostatin was demonstrated shortly after its isolation (1, 2) , its therapeutic use in GH-excess syndromes became only possible when the long-acting cyclic analogue, octreotide, was developed (3) . Intermittent (4, 5) . However, the required daily dose can vary considerably between patients, and doses of up to 1500 ng/day may be necessary (6, 7) . Since octreotide has a plasma half-time of 113 min after sc injection, GH levels tend to rise after 6-8 hours (8) . Therefore, several groups of inves¬ tigators administered octreotide by continuous sc infusion, and compared its effect with intermittent injections. In these short-term studies sc infusion of octreotide for 2-3 days was more effective in sup¬ pressing GH levels than intermittent injections (9, 10) .
The purpose of the present study was to com¬ pare the efficacy of both treatment modalities given long-term. To this effect we have investigated the effect of octreotide administration on GH-levels, as well as on a variety of other parameters, including IGF-I, thyroid hormone levels, glucose tolerance, and insulin levels in a cross-over study.
Patients and methods
Six female and 4 male patients were enrolled in this study. Fig. 1 . Integrated glucose levels were higher during treatment with the pump than during the baseline and washout studies. (p=0.013, Table 2 ). The insulin response during octreotide treatment was sluggish and the integrated incre¬ mental value during pen treatment was signifi¬ cantly lower than during the control studies (Table   o   o 2). Fasting insulin levels decreased during octreo¬ tide treatment and a similar tendency was noted during the washout period ( There were no significant changes in TSH levels. Plasma phosphate significantly decreased during pump treatment only (p=0.001).
The most significant adverse reaction noted was the presence of loose stools and abdominal cramps in all patients, which resolved spontaneously after 7-10 days of treatment.
Discussion
The present study was designed to compare the efficacy of an intermittent injection schedule with that of continuous sc infusion (CSI) of octreotide.
In acute studies GH levels were better controlled by infusion than by injections (9, 10 (6, 18, 19 (20, 21) .
A transient decrease in circulating T3 in acromegalic patients on octreotide therapy was noted in one acute study (9) 
